Oxford Biomedica (LON:OXB) Share Price Passes Above 200-Day Moving Average – Here’s Why

Oxford Biomedica plc (LON:OXB) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 665.42 and traded as high as GBX 668. Oxford Biomedica shares last traded at GBX 635, with a volume of 4,978,449 shares trading hands.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Jefferies Financial Group assumed coverage on Oxford Biomedica in a research note on Monday, March 23rd. They issued a “buy” rating and a GBX 827 price objective for the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a GBX 950 price objective on shares of Oxford Biomedica in a research note on Wednesday, March 11th. Finally, Deutsche Bank Aktiengesellschaft raised their price objective on Oxford Biomedica from GBX 735 to GBX 800 and gave the company a “buy” rating in a research note on Friday, January 9th. Six research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 687.

Oxford Biomedica Price Performance

The firm has a fifty day moving average price of GBX 644 and a 200-day moving average price of GBX 665.42. The company has a quick ratio of 1.67, a current ratio of 2.20 and a debt-to-equity ratio of 116.74. The firm has a market cap of £767.72 million, a price-to-earnings ratio of -23.59 and a beta of 1.10.

Oxford Biomedica (LON:OXB) last posted its quarterly earnings data on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%. As a group, sell-side analysts forecast that Oxford Biomedica plc will post -31.0799998 EPS for the current year.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.